

Published in final edited form as:

Cell Host Microbe. 2011 June 16; 9(6): 463–471. doi:10.1016/j.chom.2011.04.014.

***Leishmania* promotes its own virulence by inducing expression of the host immune inhibitory ligand CD200**

Mauro Cortez^{1,2}, Chau Huynh^{1,2}, Maria Cecilia Fernandes¹, Kathleen A. Kennedy³, Alan Aderem³, and Norma W. Andrews^{1,2}

¹Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD

²Section of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT

³Institute of Systems Biology, Seattle, WA

Summary

Leishmania parasites infect macrophages, cells normally involved in innate defense against pathogens. *L. amazonensis* and *L. major* cause severe or mild disease, respectively, consistent with each parasite's ability to survive within activated macrophages. The mechanisms underlying increased virulence of *L. amazonensis* are mostly unknown. We show that *L. amazonensis* promotes its own survival by inducing expression of CD200, an immunoregulatory molecule that inhibits macrophage activation. *L. amazonensis* does not form typical non-healing lesions in CD200^{-/-} mice and cannot replicate in CD200^{-/-} macrophages, an effect reversed by exogenous administration of soluble CD200-Fc. The less virulent *L. major* does not induce CD200 expression and forms small, self-healing lesions in both wild type and CD200^{-/-} mice. Notably, CD200-Fc injection transforms the course of *L. major* infection to one resembling *L. amazonensis*, with large, non-healing lesions. CD200-dependent iNOS inhibition allows parasite growth in macrophages, identifying a mechanism for the increased virulence of *L. amazonensis*.

Introduction

The parasitic protozoan *Leishmania* infects millions of people worldwide. Leishmaniasis is a growing public health threat, due to recent increases in transmission by infected sand flies. Different species of *Leishmania* cause a wide spectrum of human disease, from self-healing cutaneous lesions to lethal visceralizing infections. The parasite factors responsible for the different forms of clinical disease have not been elucidated. In this study we investigate this issue by comparing two species that cause cutaneous lesions, *L. amazonensis* and *L. major* (Afonso and Scott, 1993; Jones et al., 2002; Jones et al., 2000). Infections with *L. amazonensis* and *L. major* cause severe or mild disease respectively (Barral et al., 1991; McMahon-Pratt and Alexander, 2004) and these differences in virulence have been proposed to be associated with the ability of each pathogen to survive within activated macrophages (Barral et al., 1991; Gomes et al., 2003; McMahon-Pratt and Alexander, 2004; Qi et al., 2004; Scott and Sher, 1986). However, the molecular mechanisms responsible for

© 2011 Elsevier Inc. All rights reserved.

Corresponding author: Norma W. Andrews, Department of Cell Biology and Molecular Genetics, 2134 Bioscience Research Building, University of Maryland, College Park, MD 20742-5815, Phone (301) 405-9601, Fax (301) 314-1248, andrewsn@umd.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The authors do not have any conflicts of interest to declare.

the resistance of *L. amazonensis* to microbicidal responses and for its enhanced virulence remain largely unknown.

Immune responses of myeloid cells can be controlled by a number of inhibitory receptors (Ravetch and Lanier, 2000). Among the best characterized immune inhibitory ligand-receptors pairs is CD200 and its receptor CD200R. CD200 (OX2) is a cell surface glycoprotein from the immunoglobulin superfamily that is expressed in several cell types, particularly lymphoid cells, neurons, and endothelium (Barclay et al., 2002). CD200 has a very short intracellular tail that does not contain any known signaling motif. By engaging CD200R, a cell surface receptor that contains three conserved tyrosines in its cytosolic domain, CD200 generates an inhibitory signal that prevents local macrophage activation (Foster-Cuevas et al., 2004; Hoek et al., 2000; Wright et al., 2000). CD200R is widely expressed in myeloid cells, but resting macrophages express low, or undetectable levels of CD200 ligand (Mukhopadhyay et al., 2010). In this study we show that *L. amazonensis*, but not *L. major*, has the ability to induce macrophages to express CD200, resulting in a dampening of macrophage microbicidal responses and an increase in parasite intracellular survival and virulence.

Results

***L. amazonensis*-induced expression of CD200 in host macrophages is required for intracellular replication of the parasites**

Transcriptome analysis of C57BL/6 bone marrow macrophages (BMM) infected with *Leishmania amazonensis* detected an increase in CD200 mRNA levels. Real Time PCR analysis confirmed a marked increase in CD200 mRNA 1 h after infection of BMM with *L. amazonensis* axenic amastigotes (Fig. 1A), with a concomitant increase in CD200 protein levels (Fig. 1B). Interestingly, at 6 or 24 h after infection CD200 levels were again reduced, indicating that the signals responsible for the activation of CD200 expression are restricted to early stages of interaction the parasites with the macrophage. The small but significant increase in CD200 expression detected at 48 h after infection (Fig. 1A) may reflect re-infection of macrophages by parasites released from neighboring cells.

We found that CD200 expression was required for replication in macrophages. The number of intracellular parasites doubled approximately every 24 h in wild type (WT) BMM, while no significant growth was observed in BMM isolated from CD200^{-/-} mice (Fig. 1C and D). Importantly, treatment of CD200^{-/-} BMM with a CD200-Fc fusion protein (Snelgrove et al., 2008) rescued their ability to support the intracellular replication of *L. amazonensis*, while not affecting parasite growth in WT BMM (Fig. 1E). A control IgG1-Fc fusion protein lacking the CD200 sequence had no effect on the intracellular growth of *L. amazonensis* in BMM (S1).

CD200 expression inhibits *L. amazonensis*-induced iNOS and NO production

Nitric oxide (NO) production by inducible nitric oxide synthase (iNOS) is a major mechanism used by macrophages to kill intracellular *Leishmania* (Liew et al., 1990; Qadoumi et al., 2002; Wei et al., 1995), and to prevent reactivation of latent leishmaniasis (Stenger et al., 1996). Of particular relevance for the present studies, iNOS/NO production by macrophages also plays a prominent role during early stages of the innate immune response against *L. major*, (Diefenbach et al., 1998). Since CD200 signaling was shown to suppress iNOS-mediated generation of NO (Banerjee and Dick, 2004; Cameron et al., 2005; Copland et al., 2007), we investigated if this mechanism was involved in the enhanced survival of *L. amazonensis* after infection of CD200^{-/-} BMM. Low levels of iNOS expression was detected by western blot in wild type BMM exposed to *L. amazonensis*

axenic amastigotes, whereas higher levels were consistently observed in CD200^{-/-} BMM (Fig. 2A and B). In agreement with an involvement of iNOS in the restriction of the intracellular growth of *L. amazonensis* in macrophages lacking CD200, the specific iNOS inhibitor L-NMMA rescued parasite replication in CD200^{-/-} BMM. In contrast, the inactive isomer D-NMMA had no effect (Fig. 2C and D). A sensitive fluorometric assay revealed that NO produced by CD200^{-/-} BMM infected with *L. amazonensis* were elevated, when compared to infected wild type BMM (Fig. 2E). These NO levels were markedly lower than what is observed in infected or non-infected BMM exposed to LPS and IFN γ (S2), consistent with the observed inhibition in parasite replication instead of parasite death. No differences in iNOS transcript levels were observed between CD200^{+/+} and CD200^{-/-} infected BMM (results not shown), consistent with previous reports suggesting that *L. amazonensis* inhibits iNOS expression in host cells by a post-transcriptional mechanism (Balestieri et al., 2002; Wilkins-Rodriguez et al., 2010).

CD200 expression is required for *Leishmania* virulence *in vivo*

Next, we examined the progression of cutaneous lesions after inoculation of *L. amazonensis* into mouse footpads. Wild type CD200^{+/+} mice (WT) showed the rapidly growing, non-healing lesions that are typical of *L. amazonensis* infections in C57BL/6 mice. In sharp contrast, CD200^{-/-} mice infected with a similar parasite dose developed smaller lesions that healed by the 12th week following inoculation (Fig. 3A). Quantification of viable *L. amazonensis* in infected footpads revealed a ~100 fold expansion in the parasite population between weeks 3 and 5 in WT mice, while no significant increase was detected during the same period in CD200^{-/-} mice (Fig. 3B, S3). Thus, CD200 expression, which promotes *L. amazonensis* growth in macrophages, appears to also lead to more severe cutaneous lesions *in vivo*.

The progressive, non-healing pattern of *L. amazonensis* lesion formation in mice (Jones et al., 2002) resembles the human disease caused by this *Leishmania* species in Central and South America (Barral et al., 1991; McMahon-Pratt and Alexander, 2004). *L. major*, an agent of cutaneous leishmaniasis in the Old World, causes a more benign, self-healing form of human disease, which can be reproduced in mice of the C57BL/6 background (Belkaid et al., 2000; Jones et al., 2002). In marked contrast to *L. amazonensis*, *L. major* caused small lesions that healed within 8–9 weeks in both WT and CD200^{-/-} mice (Fig. 3C), and tissue load assays showed that CD200 deficiency did not result in any significant increase in the numbers of viable *L. major* between 3 and 5 weeks after infection (Fig. 3D, S3). These results suggested that *L. major* differs from *L. amazonensis* in its capacity to engage CD200 as a strategy for intracellular growth in macrophages.

Since *L. major* cannot be grown axenically, we used lesion-derived amastigotes from both species for our subsequent *in vitro* studies of the CD200 effect. We found that *L. major* infection, in contrast to *L. amazonensis*, did not induce CD200 transcription in BMM (Fig. 3E, S4), although infection levels with both parasite species were comparable (Fig. 3F). We also compared iNOS induction in macrophages infected with either *L. amazonensis* or *L. major*. As observed in infections performed with axenic amastigotes (Fig. 2A and B), iNOS levels with *L. amazonensis* lesion-derived amastigotes were higher in CD200^{-/-} BMM, when compared to WT BMM after 1 h of infection (Fig. 4A and B). However, the outcome of infection with *L. major* lesion-derived amastigotes was markedly different. iNOS expression was detected after 1 h of infection in both populations of BMM, independent of CD200 expression (Fig. 4A and B). These iNOS expression levels were apparently sufficient to restrict the early intracellular growth of *L. major*, since the specific iNOS inhibitor L-NMMA rescued parasite replication after 48 h in both WT and CD200^{-/-} BMM, whereas the inactive isomer D-NMMA had no effect (Fig. 4C).

The mild, self-healing course of infection with *L. major* is transformed into a virulent non-healing pattern by administration of soluble CD200-Fc

As observed with axenic amastigotes (Fig. 1C and E), *L. amazonensis* lesion-derived amastigotes grew poorly in CD200^{-/-} BMM, and extracellular addition of CD200-Fc rescued parasite replication (Fig. 5A). In contrast, *L. major* growth was limited in both WT and CD200^{-/-} BMM (Fig. 5B), consistent with the small, self-healing lesions observed in mice (Fig. 3C). Furthermore, the addition of CD200-Fc to both WT and CD200^{-/-} BMM promoted vigorous intracellular growth of *L. major* (Fig. 5B). In vivo results further supported the hypothesis that the induction of CD200 is critical for *Leishmania* virulence. Administration of CD200-Fc to *L. amazonensis*-infected WT mice resulted in slightly larger lesions and increased tissue parasite load (Fig. 5C and D). Remarkably, in vivo inoculation of CD200-Fc converted the mild *L. major* phenotype into a much more virulent one, resembling that of *L. amazonensis* including non-healing lesions and a six log increase in parasite load (Fig. 5C and D).

Discussion

Negative regulatory mechanisms within the immune system are essential to prevent pathology driven by unrestrained inflammatory responses to self and foreign antigens. The widely expressed and inducible ligand CD200 plays an important role in this process, by suppressing inflammatory responses on myeloid cells expressing CD200 receptors (CD200R) (Barclay et al., 2002). In this report, we demonstrate that the protozoan parasite *L. amazonensis* manipulates this potent immune inhibitory pathway to its advantage, by inducing the expression of CD200. In the absence of CD200, the virulence of *L. amazonensis* is attenuated to that resembling *L. major*, a strain that does not induce CD200. Concordantly, exogenous CD200 is capable of increasing the virulence of *L. major* to levels normally observed for *L. amazonensis*.

The detailed mechanism by which CD200 expression promotes *Leishmania* virulence in vivo remains to be fully elucidated. However, we found a role for inhibition of iNOS expression and NO production, a process known to be mediated by CD200 binding to CD200R (Banerjee and Dick, 2004; Cameron et al., 2005; Copland et al., 2007). Expression of iNOS (NOS2) in macrophages is stimulated by numerous cytokines and microbial products, which often act in synergistic pairs (MacMicking et al., 1997). The effect of LPS and IFN γ in inducing iNOS expression and NO-mediated killing of *Leishmania major* (Liew et al., 1990) has been the subject of numerous studies, which have largely focused on the potent microbicidal effect associated with the establishment of a Th1 helper lymphocyte response (Reiner and Locksley, 1995). However, more recent studies revealed that the role of iNOS expression in *L. major* infections is not restricted to the adaptive phase of the immune response. iNOS-mediated antimicrobial activity dependent on Type 1 interferons (IFN α , IFN β) was detected within the first day after parasite inoculation into mice, and identified as part of the innate immune response to *Leishmania* (Bogdan et al., 2000; Buxbaum, 2010; Diefenbach et al., 1998). IFN α was also shown to synergize with subactivating doses of LPS, activating macrophages to produce NO and kill intracellular *Leishmania major* (Shankar et al., 1996). The fact that we detected iNOS expression and NO production by macrophages after short periods of infection (1–6 h) adds significant additional information to the poorly understood innate response to *Leishmania*, and indicates that parasite components may be sufficient to provide the molecular signals required for this early response. Despite the detectable levels of iNOS present in isolated wild type macrophages infected with *L. amazonensis*, NO production by these cells could only be measured 18–24 h after infection. In contrast, in infected macrophages lacking CD200, iNOS levels were elevated, and resulted in detectable NO production as early as 6 h after infection. It is important to note that the NO levels we observed in these assays, using a

sensitive fluorescence based assay, are markedly lower than the levels observed after lipopolysaccharide (LPS) and IFN γ stimulation of macrophages (see S2). This observation is consistent with our finding that CD200 deficiency in macrophages impairs parasite replication over a period of 48 h, rather than parasite killing which is observed in IFN γ -activated macrophages and appears to require higher NO levels (Liew et al., 1990).

Our in vivo experiments show that the progressive cutaneous lesions typical of *L. amazonensis* infections shift to a healing pattern in CD200 deficient mice, and that *L. major*-induced lesions can be transformed into a non-healing pattern by CD200 inoculation. Taken together with our observations in isolated macrophages, these results suggest that the CD200-mediated suppression of iNOS expression seen shortly after cell entry may also play a role in the stimulation of lesion progression in vivo. However, important aspects of the long-term in vivo immune responses that develop in presence or absence of CD200 remain to be determined, such as whether CD200 expression affects the normal Th1 subset development that occurs in mice infected with *L. major* (Reiner and Locksley, 1995). It will also be of interest to determine if parasite-induced expression of CD200 plays a role in the functional impairment observed in dendritic cells infected with *L. amazonensis* (Boggiatto et al., 2009; Xin et al., 2008).

The increased susceptibility of Balb/c mice to *L. major* infection, with extensive parasite proliferation at sites of inoculation in vivo, is well documented (Nasseri and Modabber, 1979; Belosevic et al., 1989; Reiner and Locksley, 1995). In resistant mice from the C57BL/6 background, the *L. major* tissue load increases slowly in the first few weeks after infection, followed by a decline that coincides with lesion healing (Sacks and Noben-Trauth, 2002). However, very few studies have addressed in detail the rate of *L. major* replication in isolated macrophages from susceptible and resistant mouse strains. Most reports show increases in intracellular parasite numbers only after long periods of infection, such as 72 h (Blos et al., 2003), or longer. The numbers of intracellular *L. major* were reported to remain constant in the first 48 h of infection in Balb/c BMM (Muleme et al., 2009), and studies performed with C57BL/6 or CH3/HeNHSD BMM showed either a very small increase (Green et al., 1990; Mattner et al., 2000) or a reduction in parasite numbers during this period (Kuang et al., 2009). These observations are consistent with our present study, where we show that only *L. amazonensis* is able to double its numbers intracellularly every 24 h, while the number of intracellular *L. major* stays constant during this period. Our results suggest that CD200-mediated suppression of *Leishmania* intracellular growth may also influence lesion progression in vivo, although additional factors must also come into play as the acquired immune response develops in infected animals.

Consistent with the increased susceptibility of CD200^{-/-} animals to autoimmune and inflammatory diseases (Hoek et al., 2000), deficiency in CD200 or CD200R leads to exacerbated responses to infections with microbes such as influenza (Snelgrove et al., 2008) and *Neisseria meningitidis* (Mukhopadhyay et al., 2010). In those studies, the observed pathology was mediated by an uncurtailed systemic response against the pathogen, rather than an intrinsic increase in pathogen virulence. In sharp contrast with these observations, we found that CD200 deficient mice are more resistant to infection with virulent *L. amazonensis*, without any obvious evidence of additional pathology. The anti-inflammatory environment generated during *Leishmania* infections (Sacks and Noben-Trauth, 2002) may play a role in this process, by masking the damaging consequences of systemic CD200 deficiency.

CD200 is thought to control the activation of CD200R-expressing myeloid cells by establishing *trans*-cellular interactions (Barclay et al., 2002; Hatherley and Barclay, 2004).

Thus, we envision that CD200 molecules expressed in response to *L. amazonensis* infection interact with CD200R on neighboring macrophages, dampening the overall ability of the host cell population to control intracellular parasite growth through suppression of the microbicide NO. Our experiments demonstrate that signaling mediated by CD200 can suppress NO production and promote *Leishmania* growth within a homogeneous population of cultured macrophages. *In vivo*, it is conceivable that additional cell types may also respond to *L. amazonensis* infection by expressing CD200, expanding the parasites' ability to evade host microbicidal activity.

Experimental Procedures

Leishmania culture and purification

Leishmania amazonensis (IFLA/BR/67/PH8) and *Leishmania major* (clone VI, MHOM/IL/80/Friedlin) were propagated as promastigotes at 26°C in M199 media supplemented with 5% penicillin/ streptomycin, 0.1% hemin (25 mg/ml in 0.1N NaOH), 10 mM adenine and 10% FBS, pH 7.5. Metacyclic forms of *L. amazonensis* and *L. major* were purified by agglutination of stationary-phase promastigote cultures using the 3A.1 mAb (Pinto-da-Silva et al., 2005) and peanut agglutinin (Sigma) (Sacks and Melby, 2001), respectively. To generate *L. amazonensis* axenic amastigotes, cultures rich in metacyclic forms were incubated in M199 media supplemented with 0.25% glucose, 0.5% trypticase, 40 mM sodium succinate (pH 4.5), 20% FBS, 5% penicillin/ streptomycin at 2×10^6 /ml at 32°C for a minimum of 6 days, and then cultured axenically at 32°C. Parasites were washed 3 times in PBS before use in experiments. To obtain lesion amastigotes, female Balb/c mice were infected with purified metacyclic promastigotes of *L. amazonensis* or *L. major*. After 4–5 weeks the animals were euthanized and the parasites recovered from footpad lesions, as described (Sacks and Melby, 2001). The lesion homogenate rich in amastigotes was submitted to sequential 2000×g centrifugation steps to separate parasites from tissue debris.

Mouse infections and quantification of parasite load

Female wild type (WT) C57BL/6 mice (obtained from Jackson Laboratories) and CD200^{-/-} mice generated in the C57BL/6 background (Hoek et al., 2000) (obtained from Schering-Plough BioPharma) were bred and used under protocols approved by the Institutional Animal Care and Use Committee at the Yale University School of Medicine. Female WT or CD200^{-/-} 8 week old C57BL/6 mice were injected in the left hind footpad with 10^6 purified metacyclic promastigotes of *L. amazonensis* or *L. major*, and lesion progression was followed by blinded weekly measurements with a caliper. Inoculations of CD200-Fc or IgG1-Fc were done as described (Snelgrove et al., 2008), with some modifications. Mice were injected intraperitoneally with 10 µg of recombinant CD200-Fc chimera (3355-CD, R&D Systems) or control human IgG1-Fc (110-HG, R&D Systems) in PBS on days 1, 3 and 6 after infection, followed by weekly injections throughout the experiment. The total number of parasites in the injected footpad was estimated by a limiting dilution assay as previously described (Sacks and Melby, 2001; Titus et al., 1985), with minor modifications. Footpad tissues were ground in a Medimachine (Beckton Dickinson) and mechanically dissociated using a pellet pestle in 100 µl of Dulbecco's modified Eagle's medium containing 100 U/ml penicillin, 100 µg/ml streptomycin. Tissue homogenates were filtered in a 70 µm pore-size cell strainer (Falcon Products, Inc.) and serially diluted in a 96-well flat-bottom microtiter plate containing biphasic medium prepared using 30 µl of NNN medium containing 20% defibrinated rabbit blood and overlaid with 100 µl of M199 medium. The number of viable parasites was calculated from the highest dilution at which promastigote growth could be observed after 10 days of incubation at 26°C.

Affymetrix Gene Chip analysis

C57BL/6 BMM plated at 2.5×10^5 in 10 cm dishes were either not infected or infected with *L. amazonensis* amastigotes at MOI=10 for 30 min at 34°C. After infection, cells were washed 3 times in PBS and further incubated for the appropriate periods. Total RNA was isolated using Trizol (Invitrogen) and analyzed using an Affymetrix Gene Chip protocol, as previously described (Wilson et al., 2008). The Affymetrix protocol, used to analyze RNA extracted from BMM infected for 48 h with *L. amazonensis* amastigotes, was essentially as described (GeneChip Expression Analysis Technical Manual, Affymetrix). cRNA was hybridized for 16 h to Affymetrix Genechip Mouse Genome 430 2.0 Array (Affymetrix), which contain 45,000 probe sets for the analysis of 39,000 transcripts and variants from over 34,000 mouse genes. Normalization was performed using G-C-corrected robust multiarray average (GC-RMA). Identification of significantly perturbed genes was done using significance analysis of microarrays. The false positive rate was 0.1%.

Quantitative Real Time PCR (qPCR)

Real-time PCR was performed using a BioRad iQ icycler Detection system (BioRad Laboratories) using SYBR green fluorophore (BioRad Laboratories) according to the manufacturer's instructions. Oligonucleotide primers 5'-GAA TCA AAC AAT ACA GAA TG-3' and 5'-TGC CCC CCA CCA GTA ACA TGG-3' were used to amplify a portion of the *CD200* cDNA or 5'-TCA GTC AAC GGG GGA CAT AAA-3' and 5'-GGG GCT GTA CTG CTT AAC CAG-3' to amplify the control cDNA *HPRT1*. The reaction was incubated for 3 min at 95°C, and then for 45 cycles of 20 s at 95°C followed by 30 s at 55°C. Fluorescence was detected at each annealing step and the cycle threshold (C_t) was calculated by determining the point at which the fluorescence exceeded a threshold limit. All reactions were performed in triplicate and negative controls (no template cDNA) were included in each experiment. The data was normalized by the level of *HPRT1* expression in individual samples.

Quantification of Leishmania intracellular growth in macrophages

Mouse bone marrow macrophages (BMM) were prepared as previously described (Becker et al., 2009). 1×10^5 BMM were plated on glass coverslips in 3 cm dishes 24 h prior to experiments. Purified recombinant CD200-Fc (3355-CD, R&D Systems) or the control construct IgG1-Fc (110-HG, R&D Systems) were added at 2 µg/ml. The nitric oxide synthase inhibitors *N*-methyl-L-arginine (L-NMMA, active form) or *N*-methyl-D-arginine (D-NMMA, inactive form) were added at 500 µM (Sigma) (Iniesta et al., 2001; Koblish et al., 1998) for 30 min, followed by a PBS wash prior to infection. Axenic or lesion amastigotes were then added at a MOI=2 in RPMI 10% FBS for 1 h at 34°C. After invasion, cells were washed 3 times in PBS and incubated for the indicated times at 34°C. Coverslips were then fixed in 4% paraformaldehyde (PFA), and host cell and parasite DNA were stained with 10 µg/ml DAPI for 1 h, after permeabilization with 0.1% Triton-X 100 for 10 min. The number of intracellular parasites was quantified by scoring the total number of macrophages and the total number of intracellular parasites (clearly identifiable by visualization of the parasitophorous vacuole by phase microscopy) per microscopic field (100x N.A. 1.3 oil immersion objective, Nikon E200 epifluorescence microscope). The results were expressed as intracellular parasites per 100 macrophages. At least 300 host cells, in triplicate, were analyzed for each time point. For immunofluorescence, PFA fixed cells were washed with PBS, quenched with 15 mM NH_4Cl for 15 min and permeabilized with saponin/PBS (0.1 %), prior to staining with rat anti-mouse Lamp1 mAb (Developmental Studies Hybridoma Bank) for 1 h, followed by 1 h incubation with anti-rabbit IgG AlexaFluor 488. For parasite staining, coverslips were permeabilized with 0.1 % Triton-X 100 for 3 min and incubated with mouse polyclonal antibodies prepared against axenic amastigotes of *L. amazonensis*, followed by anti-mouse IgG Texas red. All samples

were incubated with 10 µg/ml DAPI for nuclei staining. Secondary antibodies were purchased from Molecular Probes. Images were either acquired through a 100x objective using a Zeiss Axiovert microscope equipped with a Hamamatsu Orca II cooled CCD camera controlled by Metamorph Software (Molecular Devices), or with a Leica SPX5 confocal microscope using a 63x/1.4 objective.

Western Blot and Immunoprecipitation

15 µg of protein/well were separated under reducing conditions on a 10% SDS polyacrylamide gel, blotted onto nitrocellulose membranes using a Trans-blot Transfer system (Bio-Rad Laboratories) overnight at 40V, and probed with rabbit anti-mouse iNOS (Abcam), and mouse anti-mouse actin (Sigma) followed by peroxidase-conjugated secondary antibodies. CD200 protein detection was performed using the Pierce Crosslink Immunoprecipitation Kit as described by the manufacturer (Thermo Scientific). Briefly, samples were added to columns containing goat anti-mouse CD200 antibodies (R&D Systems) crosslinked to protein G/A beads. After several washes elution buffer (20 µl) was added, and the eluate samples were separated under reducing conditions on a 10% SDS polyacrylamide gel, blotted onto nitrocellulose membranes, and probed with goat anti-CD200 antibodies followed by peroxidase-conjugated secondary antibodies. Immunoblots were developed using Supersignal West Pico Chemiluminescent Substrate (Thermo Scientific) and detected using a Fuji LAS-3000 Imaging System and Image Reader LAS-3000 software.

Nitric oxide measurement

Nitrite concentrations in BMM culture supernatants were used as a measure of nitric oxide production, and quantified using a Fluorometric Assay Kit (Biovision) or modified Griess reagent (Sigma), as described by the manufacturers. Before quantification, all samples were centrifuged at 800×g to remove cellular debris, and filtered in Amicon Ultra device filters (Millipore). Absorbance was measured at 450 nm after excitation at 360 nm for the Fluorometric Assay Kit, and at 540 nm for the modified Griess reagent. The concentration of nitric oxide (total nitrite concentration) in each sample was calculated from standard curve determinations as provided by the manufacturers.

Statistical analysis

Statistical significance between means of various groups was determined using an unpaired Student t test for independent samples (GraphPad Prism software). Values of 0.05 or less were considered significant.

Highlights

- *L. amazonensis* induces expression of the immunoregulatory ligand CD200 in macrophages.
- CD200 inhibits host iNOS expression and NO production, and is required for *L. amazonensis* virulence.
- *L. major* grows slowly in macrophages and mice, and does not induce CD200 expression.
- Mild *L. major* infections are transformed into a virulent pattern by soluble CD200.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

- Afonso LC, Scott P. Immune responses associated with susceptibility of C57BL/10 mice to *Leishmania amazonensis*. *Infect Immun*. 1993; 61:2952–2959. [PubMed: 8514400]
- Balestieri FM, Queiroz AR, Scavone C, Costa VM, Barral-Netto M, Abrahamsohn Ide A. *Leishmania (L.) amazonensis*-induced inhibition of nitric oxide synthesis in host macrophages. *Microbes Infect*. 2002; 4:23–29. [PubMed: 11825771]
- Banerjee D, Dick AD. Blocking CD200-CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats. *Ocul Immunol Inflamm*. 2004; 12:115–125. [PubMed: 15512981]
- Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. *Trends Immunol*. 2002; 23:285–290. [PubMed: 12072366]
- Barral A, Pedral-Sampaio D, Grimaldi Junior G, Momen H, McMahon-Pratt D, Ribeiro de Jesus A, Almeida R, Badaro R, Barral-Netto M, Carvalho EM, et al. Leishmaniasis in Bahia, Brazil: evidence that *Leishmania amazonensis* produces a wide spectrum of clinical disease. *Am J Trop Med Hyg*. 1991; 44:536–546. [PubMed: 2063957]
- Becker SM, Delamarre L, Mellman I, Andrews NW. Differential role of the Ca(2+) sensor synaptotagmin VII in macrophages and dendritic cells. *Immunobiology*. 2009; 214:495–505. [PubMed: 19157638]
- Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G, Sacks D. A natural model of *Leishmania major* infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. *J Immunol*. 2000; 165:969–977. [PubMed: 10878373]
- Belosevic M, Finbloom DS, Van Der Meide PH, Slayter MV, Nacy CA. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with *Leishmania major*. *J Immunol*. 1989; 143:266–274. [PubMed: 2499629]
- Blos M, Schleicher U, Soares Rocha FJ, Meissner U, Rollinghoff M, Bogdan C. Organ-specific and stage-dependent control of *Leishmania major* infection by inducible nitric oxide synthase and phagocyte NADPH oxidase. *Eur J Immunol*. 2003; 33:1224–1234. [PubMed: 12731047]
- Bogdan C, Rollinghoff M, Diefenbach A. The role of nitric oxide in innate immunity. *Immunol Rev*. 2000; 173:17–26. [PubMed: 10719664]
- Boggiatto PM, Jie F, Ghosh M, Gibson-Corley KN, Ramer-Tait AE, Jones DE, Petersen CA. Altered dendritic cell phenotype in response to *Leishmania amazonensis* amastigote infection is mediated by MAP kinase, ERK. *Am J Pathol*. 2009; 174:1818–1826. [PubMed: 19349356]
- Buxbaum LU. Type I IFNs promote the early IFN-gamma response and the IL-10 response in *Leishmania mexicana* infection. *Parasite Immunol*. 2010; 32:153–160. [PubMed: 20070829]
- Cameron CM, Barrett JW, Liu L, Lucas AR, McFadden G. Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. *J Virol*. 2005; 79:6052–6067. [PubMed: 15857991]
- Copland DA, Calder CJ, Raveney BJ, Nicholson LB, Phillips J, Cherwinski H, Jenmalm M, Sedgwick JD, Dick AD. Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. *Am J Pathol*. 2007; 171:580–588. [PubMed: 17600119]
- Diefenbach A, Schindler H, Donhauser N, Lorenz E, Laskay T, MacMicking J, Rollinghoff M, Gresser I, Bogdan C. Type 1 interferon (IFN α/β) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. *Immunity*. 1998; 8:77–87. [PubMed: 9462513]
- Foster-Cuevas M, Wright GJ, Puklavec MJ, Brown MH, Barclay AN. Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor. *J Virol*. 2004; 78:7667–7676. [PubMed: 15220441]

- Gomes IN, Calabrich AF, Tavares Rda S, Wietzerbin J, de Freitas LA, Veras PS. Differential properties of CBA/J mononuclear phagocytes recovered from an inflammatory site and probed with two different species of *Leishmania*. *Microbes Infect.* 2003; 5:251–260. [PubMed: 12706438]
- Green SJ, Crawford RM, Hockmeyer JT, Meltzer MS, Nacy CA. *Leishmania major* amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. *J Immunol.* 1990; 145:4290–4297. [PubMed: 2124240]
- Hatherley D, Barclay AN. The CD200 and CD200 receptor cell surface proteins interact through their N-terminal immunoglobulin-like domains. *Eur J Immunol.* 2004; 34:1688–1694. [PubMed: 15162439]
- Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). *Science.* 2000; 290:1768–1771. [PubMed: 11099416]
- Niеста V, Gomez-Nieto LC, Corraliza I. The inhibition of arginase by N(omega)-hydroxy-L-arginine controls the growth of *Leishmania* inside macrophages. *J Exp Med.* 2001; 193:777–784. [PubMed: 11257143]
- Jones DE, Ackermann MR, Wille U, Hunter CA, Scott P. Early enhanced Th1 response after *Leishmania amazonensis* infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. *Infect Immun.* 2002; 70:2151–2158. [PubMed: 11895981]
- Jones DE, Buxbaum LU, Scott P. IL-4-independent inhibition of IL-12 responsiveness during *Leishmania amazonensis* infection. *J Immunol.* 2000; 165:364–372. [PubMed: 10861073]
- Koblish HK, Hunter CA, Wysocka M, Trinchieri G, Lee WM. Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. *J Exp Med.* 1998; 188:1603–1610. [PubMed: 9802972]
- Kuang Z, Yao S, Xu Y, Lewis RS, Low A, Masters SL, Willson TA, Kolesnik TB, Nicholson SE, Garrett TJ, et al. SPRY domain-containing SOCS box protein 2: crystal structure and residues critical for protein binding. *J Mol Biol.* 2009; 386:662–674. [PubMed: 19154741]
- Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S. Macrophage killing of *Leishmania* parasite in vivo is mediated by nitric oxide from L-arginine. *J Immunol.* 1990; 144:4794–4797. [PubMed: 2351828]
- MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. *Annu Rev Immunol.* 1997; 15:323–350. [PubMed: 9143691]
- Mattner J, Schindler H, Diefenbach A, Rollinghoff M, Gresser I, Bogdan C. Regulation of type 2 nitric oxide synthase by type 1 interferons in macrophages infected with *Leishmania major*. *Eur J Immunol.* 2000; 30:2257–2267. [PubMed: 10940917]
- McMahon-Pratt D, Alexander J. Does the *Leishmania major* paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? *Immunol Rev.* 2004; 201:206–224. [PubMed: 15361243]
- Mukhopadhyay S, Pludemann A, Hoe JC, Williams KJ, Varin A, Makepeace K, Akin ML, Bowdish DM, Smale ST, Barclay AN, et al. Immune inhibitory ligand CD200 induction by TLRs and NLRs limits macrophage activation to protect the host from meningococcal septicemia. *Cell Host Microbe.* 2010; 8:236–247. [PubMed: 20833375]
- Muleme HM, Reguera RM, Berard A, Azinwi R, Jia P, Okwor IB, Beverley S, Uzonna JE. Infection with arginase-deficient *Leishmania major* reveals a parasite number-dependent and cytokine-independent regulation of host cellular arginase activity and disease pathogenesis. *J Immunol.* 2009; 183:8068–8076. [PubMed: 19923451]
- Nasseri M, Modabber FZ. Generalized infection and lack of delayed hypersensitivity in BALB/c mice infected with *Leishmania tropica major*. *Infect Immun.* 1979; 26:611–614. [PubMed: 546790]
- Pinto-da-Silva LH, Fampa P, Soares DC, Oliveira SM, Souto-Pradon T, Saraiva EM. The 3A1-La monoclonal antibody reveals key features of *Leishmania (L) amazonensis* metacyclic promastigotes and inhibits procyclics attachment to the sand fly midgut. *Int J Parasitol.* 2005; 35:757–764. [PubMed: 15885694]

- Qadoumi M, Becker I, Donhauser N, Rollinghoff M, Bogdan C. Expression of inducible nitric oxide synthase in skin lesions of patients with american cutaneous leishmaniasis. *Infect Immun*. 2002; 70:4638–4642. [PubMed: 12117977]
- Qi H, Ji J, Wanasen N, Soong L. Enhanced replication of *Leishmania amazonensis* amastigotes in gamma interferon-stimulated murine macrophages: implications for the pathogenesis of cutaneous leishmaniasis. *Infect Immun*. 2004; 72:988–995. [PubMed: 14742545]
- Ravetch JV, Lanier LL. Immune inhibitory receptors. *Science*. 2000; 290:84–89. [PubMed: 11021804]
- Reiner SL, Locksley RM. The regulation of immunity to *Leishmania major*. *Annu Rev Immunol*. 1995; 13:151–177. [PubMed: 7612219]
- Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to *Leishmania major* in mice. *Nat Rev Immunol*. 2002; 2:845–858. [PubMed: 12415308]
- Sacks DL, Melby PC. Animal models for the analysis of immune responses to leishmaniasis. *Curr Protoc Immunol*. 2001 *Chapter 19*, Unit 19 12.
- Scott P, Sher A. A spectrum in the susceptibility of leishmanial strains to intracellular killing by murine macrophages. *J Immunol*. 1986; 136:1461–1466. [PubMed: 3511147]
- Shankar AH, Morin P, Titus RG. *Leishmania major*: differential resistance to infection in C57BL/6 (high interferon-alpha/beta) and congenic B6.C-H-28c (low interferon-alpha/beta) mice. *Exp Parasitol*. 1996; 84:136–143. [PubMed: 8932763]
- Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L, Gwyer E, Sedgwick JD, Barclay AN, Hussell T. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. *Nat Immunol*. 2008; 9:1074–1083. [PubMed: 18660812]
- Stenger S, Donhauser N, Thuring H, Rollinghoff M, Bogdan C. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. *J Exp Med*. 1996; 183:1501–1514. [PubMed: 8666908]
- Titus RG, Marchand M, Boon T, Louis JA. A limiting dilution assay for quantifying *Leishmania major* in tissues of infected mice. *Parasite Immunol*. 1985; 7:545–555. [PubMed: 3877902]
- Wei XQ, Charles IG, Smith A, Ure J, Feng GJ, Huang FP, Xu D, Muller W, Moncada S, Liew FY. Altered immune responses in mice lacking inducible nitric oxide synthase. *Nature*. 1995; 375:408–411. [PubMed: 7539113]
- Wilkins-Rodriguez AA, Escalona-Montano AR, Aguirre-Garcia M, Becker I, Gutierrez-Kobeh L. Regulation of the expression of nitric oxide synthase by *Leishmania mexicana* amastigotes in murine dendritic cells. *Exp Parasitol*. 2010; 126:426–434. [PubMed: 20659463]
- Wilson J, Huynh C, Kennedy KA, Ward DM, Kaplan J, Aderem A, Andrews NW. Control of parasitophorous vacuole expansion by LYST/Beige restricts the intracellular growth of *Leishmania amazonensis*. *PLoS Pathog*. 2008; 4:e1000179. [PubMed: 18927622]
- Wright GJ, Puklavec MJ, Willis AC, Hoek RM, Sedgwick JD, Brown MH, Barclay AN. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. *Immunity*. 2000; 13:233–242. [PubMed: 10981966]
- Xin L, Li K, Soong L. Down-regulation of dendritic cell signaling pathways by *Leishmania amazonensis* amastigotes. *Mol Immunol*. 2008; 45:3371–3382. [PubMed: 18538399]

Acknowledgments

We thank Dr. A. Vignery (Yale University) for helpful discussions and Amy Beaven (University of Maryland) and the Department of Cell Biology and Molecular Genetics Imaging Core for assistance with confocal microscopy. This work was supported by NIH grants R01AI067979 and R37AI34867 to N.W.A., and R01AI025032 and R01AI032972 to A.A. Author Contributions: M.C., C.H., A.A. and N.W.A. conceived and designed the project. M.C., C.H., M.C.F and K.A.K. performed experiments. M.C., K.A.K., A.A. and N.W.A. wrote the manuscript.




Figure 1. CD200 expression is required for *L. amazonensis* growth in macrophages
(A) CD200 transcript levels measured by qPCR in BMM infected for 1 h with *L. amazonensis* axenic amastigotes, and either processed immediately or after incubation for 24 or 48 h. Results correspond to mean \pm SD of triplicates. *** $p < 0.0001$; ** $p < 0.0075$ (Student's *t* test). **(B)** Immunoblot of CD200 protein levels in BMM infected (I) or not (NI) for 1 h with axenic amastigotes. Mouse splenocytes (S) were used as a positive control. **(C)** Intracellular *L. amazonensis* over time in WT and CD200^{-/-} BMM infected for 1 h with axenic amastigotes and either fixed immediately or after incubation for 24 or 48 h. Results correspond to mean \pm SD of triplicates. * $p < 0.0270$; ** $p < 0.0035$ (Student's *t* test). **(D)** Images of *L. amazonensis*-infected WT or CD200^{-/-} BMM, 1 and 48h after infection. Nuclei were stained with DAPI (blue); parasitophorous vacuole membranes were stained with antibodies to the lysosomal glycoprotein Lamp1 (green); parasites were stained with anti-*Leishmania* antibodies (red). **(E)** Intracellular *L. amazonensis* in WT and CD200^{-/-} BMM infected for 1 h in the presence or not of CD200-Fc. Results correspond to mean \pm SD of triplicates. * $p < 0.0138$, 24 h; * $p < 0.0150$, 48 h (Student's *t* test).




Figure 2. CD200 promotes *L. amazonensis* intracellular growth by down-regulating iNOS
(A) iNOS immunoblot in WT and CD200^{-/-} BMM infected for 1 h with *L. amazonensis* axenic amastigotes and incubated for the indicated time points. No iNOS band was detected in lysates of non-infected BMM (not shown). Blots were also probed with anti-actin as a loading control. **(B)** Densitometry analysis of the data in (A), expressed as iNOS/actin ratio. **(C)** Intracellular *L. amazonensis* over time in WT or CD200^{-/-} BMM pre-treated with 500 μM D- or L-NMMA and infected for 1 h with axenic amastigotes and either fixed immediately or after incubation for 24 or 48 h. Results correspond to mean ± SD of triplicates. * p<0.0444; ** p<0.0023 (Student's *t* test). **(D)** Images of WT and CD200^{-/-} BMM pre-treated with D- or L-NMMA, 48h after infection. Nuclei were stained with DAPI

(blue); parasitophorous vacuole membranes were stained with anti-Lamp1 (green); parasites were stained with anti-*Leishmania* (red). Long arrows point to replicating amastigotes; short arrows point to single, non-replicating amastigotes. **(E)** NO levels in the supernatant of WT and CD200^{-/-} BMM measured with a fluorometric assay after 1 h infection with axenic amastigotes. Results correspond to mean \pm SD of triplicates. *** $p=0.0001$; * $p=0.038$ (18h); $p=0.014$ (24h) (Student's *t* test).




Figure 3. The reduced virulence of *L. major* is associated with its inability to induce CD200 expression

(A) Lesion size during infection of WT and CD200^{-/-} mice with *L. amazonensis*. Results correspond to mean \pm SD (n=5). * p<0.021; ** p< 0.0037; *** p< 0.0006 (Student's t test). (B) Parasite load in footpads from WT and CD200^{-/-} mice infected with *L. amazonensis*. Results correspond to mean \pm SD (n=5). ** p<0.0025; *** p< 0.0001 (Student's t test). (C) Lesion size during infection of WT and CD200^{-/-} mice with *L. major*. Results correspond to mean \pm SD (n=5). (D) Parasite load in footpads from WT and CD200^{-/-} mice infected with *L. major*. Results correspond to mean \pm SD (n=5). (E) CD200 transcript levels determined by qPCR in BMM infected for 1 h with *L. amazonensis* (green) or *L. major* (red) lesion-derived amastigotes. Results correspond to mean \pm SD of triplicates. *** p=0.0001 (Student's t test). (F) Numbers of intracellular parasites in the experiment shown in 3E. Results correspond to mean \pm SD of triplicates.




Figure 4. The reduced ability of *L. major* to replicate in macrophages is associated with induction of iNOS expression

(A) Immunoblot of iNOS in WT and CD200^{-/-} BMM infected for 1 h with *L. amazonensis* or *L. major* lesion-derived amastigotes. Anti-actin was used as loading control. (B) Densitometry analysis of the data in (A), expressed as iNOS/actin ratio. (C) Intracellular *L. major* over time in WT or CD200^{-/-} BMM pre-treated with 500 μ M D- or L-NMMA and infected for 1 h with lesion-derived amastigotes, and either fixed immediately or after incubation for 24 or 48 h. Results correspond to mean \pm SD of triplicates. ** p=0.0079 (WT); p=0.0027 (CD200^{-/-}) (Student's *t* test).




Figure 5. CD200 transforms the mild *L. major* infection into a virulent pattern typical of *L. amazonensis*

(A) Intracellular parasites in WT or CD200^{-/-} BMM infected for 1h with *L. amazonensis* lesion-derived amastigotes and either fixed immediately or after incubation for 24 or 48 h. Results correspond to mean \pm SD of triplicates. * $p < 0.0379$; ** $p < 0.0018$. (B) Intracellular parasites in WT or CD200^{-/-} BMM infected for 1h with *L. major* lesion-derived amastigotes, in the presence or not of CD200-Fc. Results correspond to mean \pm SD of triplicates. ** $p < 0.0011$; * $p < 0.0142$ (Student's t test). (C) Lesion size during *L. amazonensis* (green) or *L. major* (red) infection in WT mice, treated with CD200-Fc (open circles) or control IgG1-Fc (closed circles). Results correspond to mean \pm SD (n=5). *L.*

amazonensis: ** p= 0.038; * p=0.077; *L. major*: * p=0.039; ** p=0.005 (6th week), p=0.0054 (7th week); *** p= 0.0002 (8th week), p=0.0001 (9th week) (Student's t test). **(D)** Parasite load in footpads from the experiment in (C), 9 weeks following infection with *L. amazonensis* (green) or *L. major* (red). Results correspond to mean \pm SD (n=5). *L. amazonensis* * p=0.025; *L. major* *** p=0.0004 (Student's t test).